{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:46:20Z","timestamp":1774525580172,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT \u2013 Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, I.P.,","award":["POCI-01-0145-FEDER-029311 (ref.: PTDC\/BTM-TEC\/29311\/2017), PTDC\/NEU-NMC\/0205\/2012, UIDB\/04539\/2020, and POCI-01-0145-FEDER-016795 (ref.: PTDC\/NEU-SCC\/7051\/2014)."],"award-info":[{"award-number":["POCI-01-0145-FEDER-029311 (ref.: PTDC\/BTM-TEC\/29311\/2017), PTDC\/NEU-NMC\/0205\/2012, UIDB\/04539\/2020, and POCI-01-0145-FEDER-016795 (ref.: PTDC\/NEU-SCC\/7051\/2014)."]}]},{"name":"FCT \u2013 Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, I.P","award":["POCI-01-0145-FEDER-029516 (PTDC\/MED-NEU\/29516\/2017)"],"award-info":[{"award-number":["POCI-01-0145-FEDER-029516 (PTDC\/MED-NEU\/29516\/2017)"]}]},{"DOI":"10.13039\/501100011929","name":"Programa Operacional Tem\u00e1tico Factores de Competitividade","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-016428 (ref.: SAICTPAC\/0010\/2015)"],"award-info":[{"award-number":["POCI-01-0145-FEDER-016428 (ref.: SAICTPAC\/0010\/2015)"]}],"id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The identification of circulating biomarkers that closely correlate with Parkinson\u2019s Disease (PD) has failed several times in the past. Nevertheless, in this pilot study, a translational approach was conducted, allowing the evaluation of the plasma levels of two mitochondrial-related proteins, whose combination leads to a robust model with potential diagnostic value to discriminate the PD patients from matched controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The proposed translational approach was initiated by the analysis of secretomes from cells cultured under control or well-defined oxidative stress conditions, followed by the identification of proteins related to PD pathologic mechanisms that were altered between the two states. This pipeline was further translated into the analysis of undepleted plasma samples from 28 control and 31 PD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From the secretome analysis, several mitochondria-related proteins were found to be differentially released between control and stress conditions and to be able to distinguish the two secretomes. Similarly, two mitochondrial-related proteins were found to be significantly changed in a PD cohort compared to matched controls. Moreover, a linear discriminant model with potential diagnostic value to discriminate PD patients was obtained using the combination of these two proteins. Both proteins are associated with apoptotic mitochondrial changes, which may correspond to potential indicators of cell death. Moreover, one of these proteins, the VPS35 protein, was reported in plasma for the first time, and its quantification was only possible due to its previous identification in the secretome analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this work, an adaptation of a translational pipeline for biomarker selection was presented and transposed to neurological diseases, in the present case Parkinson\u2019s Disease. The novelty and success of this pilot study may arise from the combination of: i) a translational research pipeline, where plasma samples are interrogated using knowledge previously obtained from the evaluation of cells\u2019 secretome under oxidative stress; ii) the combined used of statistical analysis and an informed selection of candidates based on their link with relevant disease mechanisms, and iii) the use of SWATH-MS, an untargeted MS method that allows a complete record of the analyzed samples and a targeted data extraction of the quantitative values of proteins previously identified.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40035-020-00188-0","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T09:02:58Z","timestamp":1585904578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson\u2019s disease potential biomarkers"],"prefix":"10.1186","volume":"9","author":[{"given":"Sandra I.","family":"Anjo","sequence":"first","affiliation":[]},{"given":"Patr\u00edcia Val\u00e9rio","family":"dos Santos","sequence":"additional","affiliation":[]},{"given":"Luiza","family":"Rosado","sequence":"additional","affiliation":[]},{"given":"Gra\u00e7a","family":"Baltazar","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Baldeiras","sequence":"additional","affiliation":[]},{"given":"Diana","family":"Pires","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Janu\u00e1rio","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Castelo-Branco","sequence":"additional","affiliation":[]},{"given":"M\u00e1rio","family":"Gr\u00e3os","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Manadas","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"issue":"9","key":"188_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.15252\/msb.20156297","volume":"13","author":"PE Geyer","year":"2017","unstructured":"Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol. 2017;13(9):942.","journal-title":"Mol Syst Biol"},{"issue":"1","key":"188_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1878-5085-4-7","volume":"4","author":"E Drucker","year":"2013","unstructured":"Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA journal. 2013;4(1):7.","journal-title":"EPMA journal"},{"issue":"9","key":"188_CR3","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/bjc.2016.291","volume":"115","author":"S Larkin","year":"2016","unstructured":"Larkin S, Johnston H, Jackson TR, Jamieson D, Roumeliotis T, Mockridge C, et al. Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC\/MS quantitative proteomics pilot study. Br J Cancer. 2016;115(9):1078.","journal-title":"Br J Cancer"},{"key":"188_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/bs.acc.2019.04.003","volume":"92","author":"M Rosado","year":"2019","unstructured":"Rosado M, Silva R, Bexiga MG, Jones JG, Manadas B, Anjo SI. Advances in biomarker detection: Alternative approaches for blood-based biomarker detection. Adv Clin Chem. 2019;92:141\u201399..","journal-title":"Adv Clin Chem"},{"key":"188_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fnagi.2018.00305","volume":"10","author":"R He","year":"2018","unstructured":"He R, Yan X, Guo J, Xu Q, Tang B, Sun Q. Recent Advances in Biomarkers for Parkinson's Disease. Front Aging Neurosci. 2018;10:305.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"188_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol. 2019;18(6):573\u201386.","journal-title":"Lancet Neurol"},{"issue":"10","key":"188_CR7","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.jprot.2010.04.003","volume":"73","author":"MP Pavlou","year":"2010","unstructured":"Pavlou MP, Diamandis EP. The cancer cell secretome: a good source for discovering biomarkers? J Proteome. 2010;73(10):1896\u2013906.","journal-title":"J Proteome"},{"issue":"4\u20135","key":"188_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/pmic.201100346","volume":"12","author":"M Stastna","year":"2012","unstructured":"Stastna M, Van Eyk JE. Secreted proteins as a fundamental source for biomarker discovery. Proteomics. 2012;12(4\u20135):722\u201335.","journal-title":"Proteomics."},{"key":"188_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.biochi.2018.05.007","volume":"155","author":"SI Anjo","year":"2018","unstructured":"Anjo SI, Manadas B. A translational view of cells' secretome analysis - from untargeted proteomics to potential circulating biomarkers. Biochimie. 2018;155:37\u201349.","journal-title":"Biochimie."},{"key":"188_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-1-4939-9597-4_20","volume":"2024","author":"AS Haqqani","year":"2019","unstructured":"Haqqani AS, Stanimirovic DB. Prioritization of therapeutic targets of inflammation using proteomics, bioinformatics, and in Silico cell-cell Interactomics. Methods Mol Biol. 2019;2024:309\u201325.","journal-title":"Methods Mol Biol"},{"key":"188_CR11","doi-asserted-by":"crossref","unstructured":"Anjo SI, Santa C, Manadas B. SWATH-MS as a tool for biomarker discovery: From basic research to clinical applications. Proteomics. 2017;17(3\u20134):1600278.","DOI":"10.1002\/pmic.201600278"},{"issue":"2\u20133","key":"188_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejphar.2003.10.032","volume":"483","author":"J Ruffels","year":"2004","unstructured":"Ruffels J, Griffin M, Dickenson JM. Activation of ERK1\/2, JNK and PKB by hydrogen peroxide in human SH-SY5Y neuroblastoma cells: role of ERK1\/2 in H2O2-induced cell death. Eur J Pharmacol. 2004;483(2\u20133):163\u201373.","journal-title":"Eur J Pharmacol"},{"key":"188_CR13","doi-asserted-by":"publisher","first-page":"120163","DOI":"10.1016\/j.talanta.2019.120163","volume":"205","author":"SI Anjo","year":"2019","unstructured":"Anjo SI, Sim\u00f5es I, Castanheira P, Gr\u00e3os M, Manadas B. Use of recombinant proteins as a simple and robust normalization method for untargeted proteomics screening: exhaustive performance assessment. Talanta. 2019;205:120163.","journal-title":"Talanta."},{"issue":"4","key":"188_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/pmic.201400221","volume":"15","author":"SI Anjo","year":"2015","unstructured":"Anjo SI, Santa C, Manadas B. Short GeLC-SWATH: a fast and reliable quantitative approach for proteomic screenings. Proteomics. 2015;15(4):757\u201362.","journal-title":"Proteomics."},{"issue":"9","key":"188_CR15","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1021\/pr070492f","volume":"7","author":"WH Tang","year":"2008","unstructured":"Tang WH, Shilov IV, Seymour SL. Nonlinear fitting method for determining local false discovery rates from decoy database searches. J Proteome Res. 2008;7(9):3661\u20137.","journal-title":"J Proteome Res"},{"key":"188_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1471-2105-10-179","volume":"10","author":"L Sennels","year":"2009","unstructured":"Sennels L, Bukowski-Wills JC, Rappsilber J. Improved results in proteomics by use of local and peptide-class specific false discovery rates. BMC bioinformatics. 2009;10:179.","journal-title":"BMC bioinformatics"},{"key":"188_CR17","doi-asserted-by":"crossref","unstructured":"Collins BC, Gillet LC, Rosenberger G, R\u00f6st HL, Vichalkovski A, Gstaiger M, et al. Quantifying protein interaction dynamics by SWATH mass spectrometry: application to the 14-3-3 system. Nat Methods. 2013;10(12):1246.","DOI":"10.1038\/nmeth.2703"},{"issue":"1","key":"188_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2164-7-142","volume":"7","author":"RA van den Berg","year":"2006","unstructured":"van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics. 2006;7(1):142.","journal-title":"BMC Genomics"},{"issue":"2","key":"188_CR19","doi-asserted-by":"publisher","first-page":"a009332","DOI":"10.1101\/cshperspect.a009332","volume":"2","author":"C Perier","year":"2012","unstructured":"Perier C, Vila M. Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2(2):a009332.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"188_CR20","first-page":"14","volume":"81","author":"Association GAotWM","year":"2014","unstructured":"Association GAotWM. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81(3):14.","journal-title":"J Am Coll Dent"},{"issue":"3","key":"188_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"188_CR22","first-page":"572634","volume":"2011","author":"V Shukla","year":"2011","unstructured":"Shukla V, Mishra SK, Pant HC. Oxidative stress in Neurodegeneration. Adv Pharmacol Sci. 2011;2011:572634.","journal-title":"Adv Pharmacol Sci"},{"issue":"11","key":"188_CR23","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1111\/j.1432-1033.2004.04132.x","volume":"271","author":"CT Chu","year":"2004","unstructured":"Chu CT, Levinthal DJ, Kulich SM, Chalovich EM, DeFranco DB. Oxidative neuronal injury. The dark side of ERK1\/2. Eur J Biochem. 2004;271(11):2060\u20136.","journal-title":"Eur J Biochem"},{"issue":"8","key":"188_CR24","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.4161\/cc.8.8.8147","volume":"8","author":"Y Mebratu","year":"2009","unstructured":"Mebratu Y, Tesfaigzi Y. How ERK1\/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle. 2009;8(8):1168\u201375.","journal-title":"Cell Cycle"},{"issue":"1","key":"188_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcp.10119","volume":"192","author":"JL Martindale","year":"2002","unstructured":"Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol. 2002;192(1):1\u201315.","journal-title":"J Cell Physiol"},{"issue":"10","key":"188_CR26","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/sj.cdd.4401662","volume":"12","author":"RD Almeida","year":"2005","unstructured":"Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, Graos MM, et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ. 2005;12(10):1329\u201343.","journal-title":"Cell Death Differ"},{"issue":"8","key":"188_CR27","first-page":"1086","volume":"123","author":"HR Xie","year":"2010","unstructured":"Xie HR, Hu LS, Li GY. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J. 2010;123(8):1086\u201392.","journal-title":"Chin Med J"},{"issue":"4","key":"188_CR28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/ana.24014","volume":"74","author":"D Pathak","year":"2013","unstructured":"Pathak D, Berthet A, Nakamura K. Energy failure: does it contribute to neurodegeneration? Ann Neurol. 2013;74(4):506\u201316.","journal-title":"Ann Neurol"},{"issue":"12","key":"188_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrg3055","volume":"12","author":"E de Nadal","year":"2011","unstructured":"de Nadal E, Ammerer G, Posas F. Controlling gene expression in response to stress. Nat Rev Genet. 2011;12(12):833\u201345.","journal-title":"Nat Rev Genet"},{"key":"188_CR30","doi-asserted-by":"publisher","first-page":"101130","DOI":"10.1016\/j.redox.2019.101130","volume":"22","author":"SI Anjo","year":"2019","unstructured":"Anjo SI, Melo MN, Loureiro LR, Sabala L, Castanheira P, Graos M, et al. oxSWATH: An integrative method for a comprehensive redox-centered analysis combined with a generic differential proteomics screening. Redox Biol. 2019;22:101130.","journal-title":"Redox Biol"},{"key":"188_CR31","doi-asserted-by":"crossref","unstructured":"Yanagida T, Tsushima J, Kitamura Y, Yanagisawa D, Takata K, Shibaike T, et al. Oxidative Stress Induction of DJ-1 Protein in Reactive Astrocytes Scavenges Free Radicals and Reduces Cell Injury. Oxid Med Cell Longev. 2009;2(1):36\u201342.","DOI":"10.4161\/oxim.2.1.7985"},{"issue":"1","key":"188_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2119\/molmed.2015.00033","volume":"21","author":"L Mullen","year":"2015","unstructured":"Mullen L, Hanschmann E-M, Lillig CH, Herzenberg LA, Ghezzi P. Cysteine oxidation targets Peroxiredoxins 1 and 2 for Exosomal release through a novel mechanism of redox-dependent secretion. Mol Med. 2015;21(1):98\u2013108.","journal-title":"Mol Med"},{"key":"188_CR33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.freeradbiomed.2014.04.002","volume":"72","author":"Y Manevich","year":"2014","unstructured":"Manevich Y, Hutchens S, Halushka PV, Tew KD, Townsend DM, Jauch EC, et al. Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome. Free Radic Biol Med. 2014;72:210\u201321.","journal-title":"Free Radic Biol Med"},{"issue":"S3","key":"188_CR34","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1002\/ana.10483","volume":"53","author":"P Jenner","year":"2003","unstructured":"Jenner P. Oxidative stress in Parkinson\u2019s disease. Ann Neurol. 2003;53(S3):S26\u201338.","journal-title":"Ann Neurol"},{"key":"188_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/B978-0-12-385883-2.00005-9","volume":"107","author":"LJ Martin","year":"2012","unstructured":"Martin LJ. Biology of mitochondria in neurodegenerative diseases. Prog Mol Biol Transl Sci. 2012;107:355\u2013415.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"11","key":"188_CR36","first-page":"1459","volume":"68","author":"J Hardy","year":"2011","unstructured":"Hardy J, Guerreiro R, Lovestone S. Clusterin as an Alzheimer BiomarkerClusterin as an Alzheimer Biomarker. JAMA Neurology. 2011;68(11):1459\u201360.","journal-title":"JAMA Neurology"},{"issue":"11","key":"188_CR37","doi-asserted-by":"publisher","first-page":"e50237","DOI":"10.1371\/journal.pone.0050237","volume":"7","author":"E Silajd\u017ei\u0107","year":"2012","unstructured":"Silajd\u017ei\u0107 E, Minthon L, Bj\u00f6rkqvist M, Hansson O. No diagnostic value of plasma Clusterin in Alzheimer's disease. PLoS One. 2012;7(11):e50237.","journal-title":"PLoS One"},{"issue":"1","key":"188_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jalz.2013.10.007","volume":"10","author":"HM Snyder","year":"2014","unstructured":"Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 2014;10(1):109\u201314.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"188_CR39","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.parkreldis.2013.07.016","volume":"19","author":"KD van Dijk","year":"2013","unstructured":"van Dijk KD, Jongbloed W, Heijst JA, Teunissen CE, Groenewegen HJ, Berendse HW, et al. Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. Parkinsonism Relat Disord. 2013;19(12):1079\u201383.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"188_CR40","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3233\/JAD-150036","volume":"46","author":"W Jongbloed","year":"2015","unstructured":"Jongbloed W, van Dijk KD, Mulder SD, van de Berg WD, Blankenstein MA, van der Flier W, et al. Clusterin levels in plasma predict cognitive decline and progression to Alzheimer's disease. J Alzheimers Dis. 2015;46(4):1103\u201310.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"188_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/JCMM.1000102","volume":"1","author":"L Polimeno","year":"2018","unstructured":"Polimeno L, Asabella AN, Mazzocca A, De Fazio G, Polimeno R, Buquicchio R, et al. Plasma levels of Clusterin are representative of the early phase of the neurodegenerative process in Parkinson\u2019s. J Clin Mol Med. 2018;1(1):1\u20135.","journal-title":"J Clin Mol Med"},{"key":"188_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2015.12.023","volume":"361","author":"H Prikrylova Vranova","year":"2016","unstructured":"Prikrylova Vranova H, Henykova E, Mares J, Kaiserova M, Mensikova K, Vastik M, et al. Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. J Neurol Sci. 2016;361:117\u201321.","journal-title":"J Neurol Sci"},{"issue":"1","key":"188_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ajhg.2011.06.001","volume":"89","author":"C Vilari\u00f1o-G\u00fcell","year":"2011","unstructured":"Vilari\u00f1o-G\u00fcell C, Wider C, Ross Owen A, Dachsel Justus C, Kachergus Jennifer M, Lincoln Sarah J, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011;89(1):162\u20137.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"188_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","volume":"89","author":"A Zimprich","year":"2011","unstructured":"Zimprich A, Benet-Pag\u00e8s A, Struhal W, Graf E, Eck Sebastian H, Offman Marc N, et al. A mutation in VPS35, encoding a subunit of the Retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011;89(1):168\u201375.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"188_CR45","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41380-018-0221-3","volume":"24","author":"AN Vagnozzi","year":"2019","unstructured":"Vagnozzi AN, Pratic\u00f2 D. Endosomal sorting and trafficking, the retromer complex and neurodegeneration. Mol Psychiatry. 2019;24(6):857\u201368.","journal-title":"Mol Psychiatry"},{"issue":"14","key":"188_CR46","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.cub.2010.05.066","volume":"20","author":"E Braschi","year":"2010","unstructured":"Braschi E, Goyon V, Zunino R, Mohanty A, Xu L, McBride HM. Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr Biol. 2010;20(14):1310\u20135.","journal-title":"Curr Biol"},{"key":"188_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm.3983","volume":"22","author":"W Wang","year":"2015","unstructured":"Wang W, Wang X, Fujioka H, Hoppel C, Whone AL, Caldwell MA, et al. Parkinson&#39;s disease\u2013associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat Med. 2015;22:54.","journal-title":"Nat Med"},{"issue":"1","key":"188_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1078-0432.CCR-08-1805","volume":"15","author":"IP Trougakos","year":"2009","unstructured":"Trougakos IP, Lourda M, Antonelou MH, Kletsas D, Gorgoulis VG, Papassideri IS, et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin Cancer Res. 2009;15(1):48\u201359.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"188_CR49","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","volume":"5","author":"JN Mandrekar","year":"2010","unstructured":"Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315\u20136.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"188_CR50","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mds.22875","volume":"25","author":"YJ Zhao","year":"2010","unstructured":"Zhao YJ, Wee HL, Chan Y-H, Seah SH, Au WL, Lau PN, et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord. 2010;25(6):710\u20136.","journal-title":"Mov Disord"},{"key":"188_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trprot.2014.08.001","volume":"4\u20135","author":"V Licker","year":"2014","unstructured":"Licker V, Burkhard PR. Proteomics as a new paradigm to tackle Parkinson\u2019s disease research challenges. Translational Proteomics. 2014;4\u20135:1\u201317.","journal-title":"Translational Proteomics"},{"issue":"22","key":"188_CR52","doi-asserted-by":"publisher","first-page":"11033","DOI":"10.1093\/nar\/gkw880","volume":"44","author":"JA Vizcaino","year":"2016","unstructured":"Vizcaino JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44(22):11033.","journal-title":"Nucleic Acids Res"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-020-00188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40035-020-00188-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-020-00188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T23:08:48Z","timestamp":1617404928000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-020-00188-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1186\/s40035-020-00188-0","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All PD patients and control subjects signed informed consent forms, and all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}